Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides methods for identifying peptide therapeutics to treat a variety of conditions. In some embodiments, a method for identifying peptide in therapeutics to treat viral infection condition is described. In some embodiments, a method for identifying peptide therapeutics to treat cancer is described. Some embodiments related to the peptides identified by the method described herein.

Abstract: Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1.

Abstract: The present invention discloses a rapid neural response telemetry (NRT) circuit and system of a cochlear implant. The circuit comprises a stimulus generator, a signal amplifier, an analog-to-digital (A/D) converter and a calculated data memory. The stimulus generator zero charges in a nerve tissue before stimulus onset and offset, and the onset asynchrony of two continuous stimuli on the same electrode may be adjusted at will. The signal amplifier filters and amplifies nervous impulse signals that are evoked by electric stimuli and received by a collector electrode. The A/D converter can adjust the sampling frequency and start-up time, and is connected to the signal amplifier to perform A/D conversion on amplified analog signals. The calculated data memory is connected to the A/D converter to calculate and store the data undergoing A/D conversion.

Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.

Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.

Abstract: Provided herein are compositions and methods for treating, ameliorating, or preventing hepatocellular carcinoma in patients. In particular, the invention relates to methods of treating, ameliorating, or preventing hepatocellular carcinoma in a patient, comprising administering to the patient 6-methoxyethylamino-numonafide alone or in combination with sorafenib.

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

Abstract: The present disclosure provides a data processing system, method and device. The system includes a control component and a plurality of computing subcomponents coupled to the control component. The plurality of computing subcomponents respectively processes sample subsets of a sample data set under instruction of a processing procedure in the control component. For one of the plurality of computing subcomponents, at least one data element is configured to output the sample subsets of the sample data set in sequence to an embedding element based on the processing procedure in the control component. At least one embedding element is configured to receive a sample subset based on the processing procedure in the control component, map sample data in the sample subset to a multi-dimensional space based on a mapping parameter to obtain a multi-dimensional sample subset, and output the multi-dimensional sample subset to at least one backend element.

Abstract: Provided herein are compositions and methods for treating, ameliorating, or preventing hepatocellular carcinoma in patients. In particular, the invention relates to methods of treating, ameliorating, or preventing hepatocellular carcinoma in a patient, comprising administering 6-methoxyethylamino-numonafide alone or in combination with sorafenib.

Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

Abstract: A full-rate referenceless clock-data recovery architecture with neither a frequency detector nor a lock detector that allows both frequency and phase locking in a single loop. According to one embodiment, a referenceless clock data recovery (CDR) circuit, comprises a digital control circuit (DCC), a phase and strobe point detector circuit (PSPD), and an LC voltage control oscillator (LC VCO) electrically coupled to the PSPD and DCC such that a frequency of the LC VCO decreases when a negative strobe point is detected and an initial frequency of the LC VCO is higher than an input data bit rate.

Abstract: The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers.

Abstract: A full-rate referenceless clock-data recovery architecture with neither a frequency detector nor a lock detector that allows both frequency and phase locking in a single loop. According to one embodiment, a referenceless clock data recovery (CDR) circuit, comprises a digital control circuit (DCC), a phase and strobe point detector circuit (PSPD), and an LC voltage control oscillator (LC VCO) electrically coupled to the PSPD and DCC such that a frequency of the LC VCO decreases when a negative strobe point is detected and an initial frequency of the LC VCO is higher than an input data bit rate.

Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.